Randall Fincke has over 25 years of experience in the field of medical technology. In addition to multiple executive positions, he has experience in designing and developing medical devices. He has received numerous patents and FDA approvals, including biphasic defibrillation waveforms and improved applications designed to generate improved patient outcomes and more effective patient treatments. Throughout his career, he has worked closely with the FDA. Randall Fincke currently works with Advent Medical Products, a company he founded.
Biphasic waveform defibrillators have overtaken monophasic defibrillators as a critical piece of technology in external defibrillation. Initially developed for use in implantable defibrillators, the biphasic model delivers a shock to the heart through two separate vectors. Through this two-pronged approach, biphasic defibrillators are able to terminate ventricular defibrillation at a lower voltage than monophasic models can. In the most basic sense, monophasic machines send a jolt of energy from one paddle to the next, while a biphasic model passes the current back, requiring less energy and resulting in less myocardial damage.
These developments as a result of extensive design and testing can make a significant difference in patient outcomes and have become an important new standard for more effective treatments.